This report provides a comprehensive financial analysis of Ingevity Corp, a specialty chemicals and materials provider, covering stock performance, analyst ratings, earnings expectations, and ownershi
Ingevity Corporation shares surged 30.6% over the past year, outperforming the industry through strategic portfolio optimization and capacity investments. Strong cash flow and disciplined capital allo
Ingevity Corp shares rose 3.4% but trade 87.9% above fair value per GF Value™. A GF Score of 56 and insider selling suggest caution despite high momentum.
Ingevity Corp's stock outperformed Basic Materials peers with a 15.3% year-to-date gain, driven by increased earnings consensus estimates. Solstice Advanced Materials also performed strongly in the sa
The global coal-based activated carbon market is projected to reach USD 3,731.85 million by 2026, growing at a 6.54% CAGR through 2033. Key drivers include environmental regulations and pollution cont
Multiple ETFs include Ingevity Corporation (IGX) in their holdings, primarily within small-cap and materials-focused funds. The report details key metrics such as market value, stock weight, and expen
Ingevity Corp stock declined recently despite receiving TIME's Best Companies 2026 recognition. Analysts debate valuation with views citing 16.9% undervaluation against a high P/E ratio of 100.9x.
Ingevity shares gained 81% over the past year, but a 100.9x P/E ratio suggests overvaluation against industry peers. Strong execution may justify the premium, though earnings misses could trigger a va
The global asphalt emulsifiers market is projected to reach USD 3.6 billion by 2036 with a 5.4% CAGR, driven by pavement preservation programs. Key players like Ingevity, Nouryon, and Arkema focus on
Ingevity Corp reported encouraging underlying earnings numbers despite a stagnant stock price. Its negative accrual ratio suggests free cash flow significantly exceeds statutory profit, indicating str
Ingevity Corporation reported a Q2 2026 profitability swing with $35.3 million net income and initiated a share repurchase program. While raised guidance supports their strategy, risks from cyclical d
Analysts rank Ingevity Corp third among 65 chemical companies with a Buy trend, presenting updated earnings forecasts and revenue growth estimates alongside peer comparisons.
Ingevity Corporation released its 2025 Sustainability Report, highlighting how its advanced materials and technologies support environmental goals like reduced emissions and cleaner water while adheri
Ingevity Corporation released its 2025 Sustainability Report, detailing how its advanced materials and technologies assist customers in achieving environmental goals through emission reduction and ren
Ingevity Corp's General Counsel Ryan Fisher sold 2,709 shares on August 3, 2026, totaling approximately $200,000 in open market transactions not executed under a Rule 10b5-1 plan.
Ingevity Corp filed an SEC Form 144 for the proposed sale of 2,709 shares worth approximately $199,703.80, executed through Morgan Stanley Smith Barney LLC.
Ingevity Corp (NGVT) ranks 31st out of 65 in the Chemicals industry with a risk score of 6.25. The assessment details volatility metrics such as beta, VaR, and liquidity indicators.
Ingevity Corporation raised its 2026 EBITDA and free cash flow guidance following a strong second-quarter performance report.
Ingevity Corp (NGVT) ranks 14th among 65 chemical companies with a valuation score of 8.94 and a P/E ratio of -21.40, while other key metrics remain undisclosed.
Ingevity Corp (NGVT) ranks first in the Chemicals industry with an institutional confidence score of 10.00, reflecting a 12.55% quarter-over-quarter increase in institutional shareholding.
Analysts rate Ingevity Corp as 'Outperform' with a $63 price target, though rising short interest indicates some bearish sentiment.
Ingevity Corporation reported 994.12 million EUR in revenue last year, with its Performance Materials segment contributing 516.73 million EUR. The United States was the largest regional contributor at
Ingevity Corp released its quarterly and annual cash flow statements, detailing operating, investing, and financing activities. The document highlights key financial metrics such as capital expenditur
Ingevity Corp receives a stable financial health rating of 7.13 within the Chemicals industry, despite a 9.15% drop in quarterly revenue and a 191.71% decline in net profit year-over-year.
Ingevity Corp shares may be overvalued despite the positive regulatory approval of Evotherm P35 in Germany. Analysts note the stock's future depends on sustaining demand in higher-value applications b
AI models analyze Ingevity Corporation (NGVT) for trading strategies, indicating strong near-term sentiment and a positive long-term bias. The report outlines three strategies—Position Trading, Moment
Ingevity's Evotherm P35 warm-mix additive received BASt approval in Germany for asphalt applications after rigorous testing. This milestone highlights the company's capability to adapt sustainable bio
Ingevity Corp outlines key metrics for its 3.875% bond maturing November 2028, detailing face value and coupon rates alongside its Performance Chemicals and Materials business segments.
Ingevity Corp cautions that its high Return on Equity (ROE) might be deceptive due to significant debt levels, elevating future risks. Investors are urged to factor in future profit growth and necessa
Ingevity Corporation reports earnings growth driven by strong demand for hybrid vehicle materials and portfolio optimization. Management anticipates long-term expansion in this sector, reshaping the i
Ingevity Corp director Francis David Segal was granted 328 vested deferred stock units valued at $72.58 per share in lieu of quarterly fees, increasing his direct holdings to 8,612 shares.
Ingevity Corporation announced it will release its second quarter 2026 earnings on July 29, 2026, followed by a live webcast discussion on July 30. Registration details for the event are available on
Ingevity Corporation has appointed Ryan Cotterman as Vice President and Chief Accounting Officer to enhance financial oversight, offering a $345,000 base salary plus performance incentives.
Ingevity Corp financial overview includes stock price, market cap, and earnings estimates. The company does not pay dividends and has a scheduled next earnings report.
TradingView displays the Enterprise Value to Revenue Forward metric for Ingevity Corporation (NYSE: NGVT), focusing on financial valuation data without in-depth analysis.
Financial data for Ingevity Corporation (FWB:IGX) highlights its enterprise value to revenue forward metric, noting that market data is currently closed with no recent trades.
Ingevity Corp submitted a Form 4 filing to the SEC on June 24, disclosing material changes in insider holdings. The document confirms regulatory compliance for the specialty chemical manufacturer.
Ingevity Corporation appointed Ryan Cotterman as Vice President and Chief Accounting Officer effective June 22, 2026, with a compensation package including a $345,000 base salary and equity incentives
Analysts estimate Ingevity stock is 14% undervalued at $73.41 versus a fair value of $85.50, driven by a strategic shift toward higher-growth specialty chemicals. However, a price-to-sales ratio above
Ingevity Corp (NGVT) ranks 35th in the Chemicals industry with a financial score of 7.20. The company reported a 9.15% year-over-year decrease in quarterly revenue and a 191.71% decrease in net profit
Ingevity Corp secured the top institutional shareholding score of 10.00 among 68 chemical companies. Institutional ownership increased 12.55% quarter-over-quarter to 120.12%, led by Chuck Royce.
Ingevity Corp (NGVT) holds an earnings forecast score of 8.00, ranking sixth within the Chemicals industry. Analyst consensus indicates a "Buy" trend with a $67.50 target price based on expected reven
Ingevity Corp promoted sodium-ion batteries as part of U.S. energy security efforts, leveraging its specialty chemicals portfolio. While financial projections show earnings growth by 2029, immediate p
Ingevity Corp trades undervalued at US$71.75 as it pivots toward specialty chemicals and sodium-ion battery materials to improve margins. Analysts project significant earnings growth despite current d
Ingevity shares dropped 12% recently despite positive yearly returns, with analysts claiming a 21.7% undervaluation linked to anticipated margin improvements from portfolio repositioning.
Ingevity Corporation is set to report first-quarter earnings with analysts expecting $83 cents per share on $279 million revenue. The company focuses on margin gains and cash generation following its
Ingevity reported Q1 2026 sales growth of 4% to $258 million, driven by Performance Materials and Pavement Technologies. The company reaffirmed full-year guidance and accelerated share repurchases aft
Ingevity Corp Senior VP Terrance Dyer sold 496 shares on May 28, 2026, bringing his total ownership to 7,202 shares. The transaction occurred while the stock was valued significantly above GuruFocus's
Ingevity Corp SVP and Chief Human Resources Officer Terrance Dyer sold $33,970 in stock on May 28, 2026. The transaction follows a 64% rise in share price over the past year, despite Q1 revenue missin
Ingevity Corp's SVP and Chief HR Officer, Terrance M. Dyer, sold 496 shares in open-market transactions on May 28, 2026, totaling approximately $34,000.
ChemBrief